Replies to post #189153 on Biotech Values

[DewDiligence]

Who would benefit from the trial of a drug seen as likely to fail in P3, and why would a pharma pay for such a trial?

Company management benefits greatly—compared to the alternative of acknowledging failure and shutting down operations; this is what Zebra’s Law is all about (#msg-111988739).

[masterlongevity]

thats a different question. presumably the NPV is positive for a pharma to move forward, or they are just playing a shell game